Home › Conferences › AASLD
AASLD The Liver Meeting 2026
Nov 5-9, 2026 · Denver, US · Hepatology / MASH.
DatesNov 5-9, 2026
LocationDenver, US
Therapeutic focusHepatology / MASH
Biotech presenters tracked0
Biotech presenters
Presenter list populates as abstracts are released.
Presenter history
We have tracked 20 biotech presentations by 14 companies across 3 past AASLD meetings (2023-2025). Upcoming presenters populate as abstracts are released. See the conference run-up study for how these names behaved into the meeting.
About · Corrections · Changelog · Glossary · Methodology
Not affiliated with AASLD or its organizer. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.
© 2026 pdufa.bio. All rights reserved.
Not affiliated with AASLD or its organizer. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.
© 2026 pdufa.bio. All rights reserved.
How AASLD stocks have traded historically
Median share-price move around a presentation, measured across 41 AASLD presentations in our study (2017-2026).
30 days before-2.22% 49% rose · n=41
10 days before-0.28% 46% rose · n=41
Presentation day+0.33% 51% rose · n=41
5 days after+2.15% 56% rose · n=41
10 days after+2.39% 61% rose · n=41
By company size (10-day run-up → 5 days after)
Small ($300M-$2B)+0.92% into it → -0.22% after n=14
Read the whole row, not just the first line: across this study stocks have drifted up into these meetings and down out of them, and the effect is largest in the smallest companies. Medians are shown because a handful of large moves pulls an average away from the typical case. This is a historical distribution for a cohort of companies, not a forecast for any single company, and not investment advice. Methodology and the full study.
FAQ
When is AASLD 2026?
AASLD The Liver Meeting 2026 runs November 5-9, 2026 in Denver, US. The date comes from the organiser's own announcement; check the organiser's site for the final programme.
Which biotech companies are presenting at AASLD 2026?
None sourced yet. We list a company as presenting only when its own SEC filing or press release commits to this edition -- abstract titles and rumours don't qualify. The conferences page updates as filings land.
How do biotech stocks typically trade around AASLD?
In our study of 41 AASLD presentations (2017-2026), the median stock moved -0.28% over the 10 trading days before the presentation (46% of them rose), +0.33% on the day itself, and +2.15% over the 5 trading days after. The pattern across the whole study is a drift up into these meetings and down out of them, strongest in the smallest companies. That is a historical distribution for a cohort, not a prediction for any one company, and not investment advice.
Why do medical conference dates matter for biotech stocks?
Trial results are often presented first at medical meetings, so a company's announced presentation is a dated, public catalyst. We publish a study of how biotech stocks have historically traded into conference presentations on the research page; it is historical measurement, not a prediction, and none of this is investment advice.